W
TARO

Wealthfront’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Wealthfront’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-28
Closed -$4K – 1124
2015
Q3 		$4K Buy
+28
New +$3.92K ﹤0.01% 1138

Other funds holding TARO

ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
GCM
Greywolf Capital Management Purchase, New York $67.3M AUM 100.05% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
TI
Think Investments San Francisco, California $762M AUM 33.1% 1-Year Est. Return
AIM
Assured Investment Management New York $79.5M AUM 115.55% 1-Year Est. Return

Wealthfront's TARO Position: Q4 2015 in Review

Wealthfront sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q4 2015, closing a stake of 28 shares — an estimated $4K sold.

Wealthfront first reported a position in TARO in Q3 2015 and held it in 1 quarter. The position peaked at $4K in Q3 2015. 153 funds tracked by Wall St. Rank hold TARO as of Q4 2015.

  • Wealthfront reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q4 2015 after selling out during the quarter.
  • Wealthfront sold 28 Taro Pharmaceutical Industries Ltd. shares in Q4 2015, an estimated $4K.
  • Wealthfront first reported a position in Taro Pharmaceutical Industries Ltd. in Q3 2015 and held it in 1 quarter.
  • Wealthfront's Taro Pharmaceutical Industries Ltd. position peaked at $4K in Q3 2015.
  • 153 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q4 2015.

Based on Wealthfront's 13F filing for Q4 2015, filed 17 Feb 2016.